US 6,187,799 B1Granted

Inhibition of raf kinase activity using aryl ureas

AssigneesOnyx Pharmaceuticals, Inc., Bayer Aktiengesellschaft

InventorsJill E Wood, Hanno Wild, Daniel H Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum

Life of this patent

Estimating the term…

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Dependent claims

A method for the treatment of cancerous cell growth mediated by raf kinase, comprising administering a compound of the formula:

Dependencies are inferred from the claim text.

C07D 207/34
Having two double bonds between ring members or between ring members and non-ring members: with hetero atoms or with carbon atoms having three…
A61P 35/00
Antineoplastic agents
C07D 307/68
With hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals,…:…
C07D 333/38
With hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals,…:…

From the US filing history. Foreign family members aren’t listed.

Loading patent…